Cost-effectiveness of electrical stimulation therapy in the treatment of chronic wounds: a systematic review, metaanalysis and economic analysis in the context of the NHS

Authors: Jennifer Smith [1]; John Posnett [2]; Emma Woodmansey [3]

Affiliations: [1] JMS Medical Writing Service Ltd, York, UK; [2] Independent Health Economist; [3] Principal Consultant, Clinical & Scientific Solutions; Senior Honorary Lecturer Cardiff University CF14 4YS

Introduction: Hard-to-heal wounds are a major burden to healthcare systems [1]. Electrical stimulation therapy (EST) is an advanced wound technology with a large body of evidence supporting improved clinical outcomes. However, robust costeffectiveness analysis of this treatment type, based on a meta-analysis approach, is lacking. The aim of this study was to robustly explore the costeffectiveness of EST in addition to standard of care (SoC) versus SoC alone to ascertain if this therapy could lead to cost savings.

Method: A systematic review and meta-analysis of randomised controlled studies (RCTs) was conducted according to the PRISMA guidelines. A cost-effectiveness model was developed based on the findings of the meta-analysis, and on the clinical usage and cost of the EST device* used in the of the largest included RCT [2] which involved treatment in the patient's own home, with no additional HCP or clinic visits needed. Weekly costs of community wound care were taken from published estimates [3] and inflated to 2024 levels [4], reflecting costs of community treatment of hard-to-heal wounds to the NHS. The cost-effectiveness analysis modelled costs and resource use associated with the wound treatment of a hypothetical cohort of 100 patients followed over a 12-week time horizon, treated with either EST + SoC or SoC alone. A sensitivity analysis varied assumptions about the clinical benefits of EST, specifically the time to healing and the proportion of ulcers healed.

Results: Fourteen RCTs with relevant data (proportion of wounds healed and/or time to healing) were identified, representing 783 patients with various chronic wound aetiologies (diabetic foot ulcers, pressure ulcers and venous leg ulcers) [2, 5-17].

Versus SoC alone, EST + SoC, increased the proportion of wounds healed from 26.9% to 48.9% (a 22% improvement), and significantly increased the likelihood of wound healing more than two-fold (odds ratio [OR] 2.46 [95% CI, 1.75-3.46], p<0.0001; **Figure 1**).

	EST + SoC		SoC + sham device			Odds ratio	Odds ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI		
Lundeberg 1992	10	32	4	32	7.1%	3.18 [0.88 , 11.52]	-		
Jercinovic 1994	58	81	15	28	14.9%	2.19 [0.90 , 5.30]	-		
Baker 1996	35	67	6	25	10.9%	3.46 [1.23 , 9.75]			
Peters 2001	13	20	7	20	6.9%	3.45 [0.94 , 12.65]	-		
Adunksy 2005	5	35	3	28	5.0%	1.39 [0.30 , 6.39]			
Houghton 2010	6	16	5	18	5.6%	1.56 [0.37 , 6.62]	-		
Polak 2016a	15	29	7	31	9.4%	3.67 [1.21 , 11.18]			
Polak 2016b	12	25	7	24	8.4%	2.24 [0.69 , 7.29]	-		
Polak 2017	14	23	4	20	6.2%	6.22 [1.57 , 24.71]			
Guest 2018	15	43	14	47	14.9%	1.26 [0.52 , 3.06]	-		
Elio 2020	10	10	8	10	1.2%	6.18 [0.26 , 146.78]	-		
Avendaño-Coy 2022	3	15	0	15	1.3%	8.68 [0.41 , 184.28]	-		
Tuson 2024	12	29	6	22	8.2%	1.88 [0.57 , 6.21]			
Total (Walda)		425		320	100.0%	2.46 [1.75 , 3.46]	•		
Total events:	208		86						
Test for overall effect:	Z = 5.15 (F	o < 0.0000	01)				0.01 0.1 1 10 100		
Figure 1. Forest plot showing proportion of wounds healed with EST compared with control							rol Favours EST +		

Versus SoC alone, EST + SoC, significantly decreased the mean time to healing by 2.67 weeks (95% CI, 1.49-3.84, p<0.00001).

	E:	ST + SoC		SoC /	SoC + sham			Mean difference	Mean difference
Study or Subgroup	Mean [Weeks]	SD [Weeks]	Total	Mean [Weeks]	SD [Weeks]	Total	Weight	IV, Random, 95% CI [Weeks]	IV, Random, 95% CI [Week
Adunksy 2005	9.05	2.16	35	12.8	1.3	28	27.8%	-3.75 [-4.61 , -2.89]	-
Elio 2020	5.2	4.34	10	6.8	4.34	10	7.4%	-1.60 [-5.40 , 2.20]	
Guest 2018	10.4	2	43	14	2	47	28.1%	-3.60 [-4.43 , -2.77]	-
Peters 2001	6.8	3.4	20	6.9	2.8	20	17.4%	-0.10 [-2.03 , 1.83]	
Polak 2017	4.33	3.73	23	6.8	1.79	20	19.3%	-2.47 [-4.18 , -0.76]	
Total (Wald ^a)			131			125	100.0%	-2.67 [-3.84 , -1.49]	•
Test for overall effect:	Z = 4.44 (P < 0.0	00001)							10 -5 0 5
Test for overall effect: Figure 2. Fores	st plot showii	ng time to	healin	g (weeks) w	ith EST co	ompare	ed with		

Cost-effectiveness analysis, concluded that in patients with hard to heal wounds, treatment with EST + SoC could save more than £38,000 in overall treatment-related costs, reduce nursing visits by 385 visits and lead to 154 more ulcer-free weeks per 100 patients treated over a 12-week period, compared with treatment with SoC alone.



Cost savings of £38,226



154 more wound-free weeks



385 fewer nurse visits

A sensitivity analysis varied the additional % of patients treated with EST who could be expected to heal versus SoC (from 22%, derived from the meta-analysis to 0%, to represent a conservative approach) and also varied the expected reduction in the speed to healing (from -3.94 weeks to -1.49, based on the confidence intervals from the meta-analysis; **Table 1)**. The lower costs observed with EST were largely driven by reducing the duration of treatment (achieving faster healing). With the addition of EST to SoC, overall costs remained lower in all of the modelled scenarios.

Reduced time to	Additional % healed with addition of EST to SoC								
healing as a result of adding EST to SoC	22% (base case from meta-analysis)	11% (half of base case)	5.5% (quarter of base case)	0% (no effect on proportion healed)					
2.67 weeks faster (mean estimate from base case)	£38,226 savings	£33,464 savings	£31,088 savings	£28,712 savings					
1.49 weeks faster (lowest estimate from base case)	£25,424 savings	£15,409 savings	£10,414 savings	£5,418 savings					
3.94 weeks faster (highest estimate from base case)	£50,919 savings	£51,365 savings	£51,587 savings	£51,809 savings					

Table 1. Sensitivity analysis of the cost-effectiveness data.

Discussion and conclusion: EST + SoC increases the proportion of wounds which achieve healing compared with SoC alone. A novel finding from the meta-analysis was that EST + SoC heals wounds significantly faster than SoC alone. This combination of clinical benefits translated into significant cost and resource savings compared with SoC alone. In particular, cost savings were closely linked with patient benefits in the form of more ulcer-free weeks. A cost-effectiveness analysis based on the findings of the meta-analysis showed that the addition of EST to standard care is not only expected to improve outcomes for patients but also to reduce costs for the NHS and is a cost-effective adjunct to standard care in non-healing wounds



References

1. Sen CK. Adv Wound Care (New Rochelle). Dec 2023;12(12):657-670; 2. Guest JF, Singh H, Rana K, Vowden P. J Wound Care. 2018;27(4):230-243; 3. Guest JF, Ayoub N, McIlwraith T, et al. Int Wound J. Apr 2017;14(2):322-330; 4. Kent Academic Repositor Unit. Accessed from https://kar.kent.ac.uk/109563/ Last accessed 6 August 2025.; 5. Tuson, R., et al. Int J Environ Res Public Health 19 (2022); 7. Elio, C., Fontani, V., et al. Acta Dermatovenerol Alp Pannonica Adriat 29, 109-113 (2020); 8. Polak, A. et al. Phys Ther 97, 777-789 (2016); 10. Polak, A. et al. J Wound Care 25, 742-754 (2016); 11. Houghton, P. E. et al. Arch Phys Med Rehabil 91, 669-678 (2010); 12. Jünger, M., et al. Wound repair and regeneration 16, 480-487 (2008); 13. Adunsky, A. & Ohry, A. Arch Gerontol Geriatr 41, 261-269 (2005); 14. Peters, E., et al. Arch Phys Med Rehabil 82, 721-725 (2001); 15. Baker, L., et al. Wound Repair Regen 4, 21-28 (1996); 16. Jercinovic, A. et al. IEEE transactions on Rehabilitation Engineering 2, 225-233 (1994); 17. Lundeberg, T. et al. Ann Plast Surg 29, 328-331 (1992).

(sham device / no device)

control (sham device / no device)